**Original Research Article**

**Prevalence of *blaTEM,* *blaSHV*, and *blaCTX-M* Genes among ESBL-Producing *Escherichia coli* Isolated from the blood samples of ICUs patients of university hospitals in Sana'a city, Yemen**

**ABSTRACT**

**Aim and Objective:** With the emergence of organisms such as Enterobacteriaceae that produce extended-spectrum β-lactamase (ESBL), which are resistant to multiple medications (multidrug-resistance), concerns about how best to treat infections have significantly increased. The current study examined the molecular features of ESBL in clinical isolates of Escherichia coli that resulted in bloodstream infections as well as the pattern of antibiotic resistance to gather useful data on the infection's epidemiology among Yemeni ICU patients.

**Subjects and methods**: A cross-sectional study was conducted on sepsis patients admitted in intensive care units at four hospitals in Sana'a, Yemen, between January, 2021 and April, 2022. Blood cultures were used on patients suspected of having sepsis. Standard laboratory procedures were then used to isolate and identify possible bacterial infections, and the disk diffusion method was used to test for microbial susceptibility. All strains were tested for Extended Spectrum Beta-Lactamase (ESBL) production using the Modified Double Disc Synergy Test (MDDST). Following analysis, polymerase chain reaction, β-lactamase genes (*bla*TEM, *bla*SHV, and *bla*CTX-M) were identified.

**Results:** The results of the conventional PCR experiment revealed that 33.3% of the *bla*CTX-M genes, 0.0% of *bla*SHV, and 100% of *bla*TEM were present in the strains of ESBL-producing *E. coli* that were collected. It was discovered that the *E. coli* isolates' patterns of antibiotic resistance to 23 different antibiotics differed greatly. The bulk of the *E. coli* isolates were found to be multi-drug resistant (MDR). Furthermore, MDR characteristics were observed in 85% of *E. coli* isolates.

**Conclusion**: Control and surveillance of antibiotic resistance depend on an understanding of the resistance genes and patterns of antimicrobial resistance of bacterial pathogens within a given geographic area. The current study's findings showed that MDR was very common. Furthermore, it was discovered that the antimicrobial agents with the highest level of activity in vitro were carbapenems and amino glycosides. According to the current study's findings, TEM was significantly more common than other ESBL gene types.

 **Keywords**: *bla*CTX-M, *bla*SHV, *bla*TEM, Blood stream infections (BSIs), ESBL, *Escherichia coli*, ICUs, Multi-drug resistant (MDR)

**INTRODUCTION**

Numerous nosocomial illnesses worldwide have been documented to have bacteria from the *Enterobacteriaceae* family as their causative cause. Given the limited therapy options resulting from the organisms' ongoing rise in antibiotic resistance, infections caused by bacilli *Enterobacteriaceae* are challenging to control. Indeed, one of the most well-known resistance mechanisms in Gram-negative bacilli was first described by Ojdana *et al.*1 and involves ESBLs. A class of enzymes known as ESBLs increases the resistance to cephalosporins, penicillins, related β-lactams, ceftazidime, and acetaminophenolactams, however clavulanic acid inhibits ESBLs1. The three primary categories of ESBLs are TEM, SHV, and CTX-M. The rapidly growing CTX-M family, which is now more common than SHV and TEM, is found in a wide variety of clinically significant bacteria and over large geographic regions2. Treatment plans become more complicated because organisms that produce ESBL frequently show resistance to antibiotics from other classes, such as quinolones, aminoglycosides, and sulfonamides3. Furthermore, members of the *Enterobacteriaceae* family, like *Escherichia coli*, frequently produce ESBLs; yet, it has recently been shown that some additional enzymes may be present in other *Enterobacteriaceae* family genera. It was initially discovered that patients in European intensive care units who had extended hospital stays exhibited a greater degree of resistance in these organisms. Nevertheless, isolates were found in South and North America, Africa, Asia, the Middle East, and Africa, and ESBL GNB quickly spread around the world4.

Common ESBL genes that code for E. Coli isolates were identified as TEM (discovered and isolated in the early 1980s from Teminora, a Greek patient), and CTX-M (cefotaximase that preferentially hydrolyzes cefotaxime). There are occasional descriptions of these transposon-, plasmid-, and chromosome-mediated genes all over the world5.

Every year, the rates of bacterial resistance rise, raising concerns around the world. For this reason, it is crucial to understand susceptibility patterns because improper empirical antimicrobial therapy can lengthen hospital stays and increase mortality rates, both of which can be prevented with the right therapy6. Acquiring additional PBPs in sensitive to ß-lactam or changing the normal PBPs are known as the commonest cause of resistance in *cocci* such as MRSA and *pneumococci* which are gram positive. However, a mixture of endogenous acquired ß-lactamases with natural efflux and up-regulated impermeability is the main reason for resistance in the gram-negative bugs7. It should be mentioned that there are well-written materials demonstrating how standard disc diffusion tests are unable to identify the development of ESBLs. There might not be enough resources in labs to stop the spread of these resistance mechanisms since many clinical laboratories do not completely understand the importance and detection technique of ESBLs8.

There are many different types of ESBLs, such as SHV, TEM, OXA, CTX, AmpC, and so on; however, the majority of them are derived from the SHV, TEM, and CTX-M enzymes, which are most frequently present in *E. coli*. In light of this, the current work examined the presence of *bla*SHV, *bla*CTX-M, and *bla*TEM genes in isolates of *E. coli* from the bloodstream of intensive care unit patients at tertiary hospitals in Sana'a, Yemen, in order to ascertain the prevalence of the ESBL phenotype.

**SUBJECTS AND METHODS**

**Isolates of bacteria:**Twenty consecutive non-duplicate *E. coli* isolates were recovered from blood culture specimens of ICU patients suffering from sepsis. A cross-sectional study was conducted on sepsis patients admitted in intensive care units at four hospitals in Sana'a, Yemen, between January, 2021 and April, 2022. Blood cultures were performed on patients suspected of having sepsis, and possible bacterial infections were subsequently isolated and identified using conventional laboratory procedures9. To identify the isolates, standard microbiological methods were used. Additionally, they were re-identified using the VITEK 2 compact system (BioMerieux, France).

**Ethic approval:** All of the techniques employed in this study were authorized by the research and ethics committee of the Faculty of Medicine and Health Sciences at Sana'a University, Sana'a, Yemen (Approval No. UGR/SU-223).

**Antimicrobial susceptibility testing:**The isolates were screened using the disc diffusion method (Kirby-Bauer disc diffusion method) on Mueller-Hinton agar (MHA) plates in accordance with the criteria of the Clinical and Laboratory Standards Institute (CLSI) to determine their antibiotic susceptibility [10]. Amoxicillin+Clavulanic acid (20+10μg), Amikacin (10μg), Azithromycin (15μg), Cefotaxime (30μg), Ceftazidime (30μg), Cefazoline (30μg), Cephradin (30μg), Cefoxitin (30μg), Cefuroxime (30μg), Ceftriaxone (30μg), Cefoperazone (30μg), Cefepime (30μg), Co-Trimoxazole (25μg), Ciprofloxacin (10μg), Imipenem (10μg), Gentamicin (10μg), Meropenem (10μg), Norfloxacin (10μg), Moxifloxacin (10μg), Piperacillin (100μg), and Tobramycin (10μg).

**Testing for production of ESBL (MDDST):** A disc containing four cephalosporins (Ceftriaxone, 3GC-Cefotaxime, 4GC Cefepime, and Cefpodoxime) and amoxicillin-clavulanate (20/10 μg) was used in the Modified Double Disc Synergy Test (MDDST) to assess each strain's ability to produce Extended Spectrum Beta-Lactamase (ESBL). On a Mueller-Hinton agar plate, a lawn culture of the organisms was established in accordance with CLSI guidelines10. Placing a disc in the center of the plate held 20/10 μg of amoxicillin-clavulanate. The amoxicillin-clavulanate disc's center was positioned 15 mm and 20 mm from the center of the 3GC and 4GC discs, respectively11. Any expansion or deformation in the zone toward the disc of amoxicillin and clavulanate was considered indicative of ESBL development. The combined disc test was used to validate ESBL production in accordance with CLSI recommendations.

**Detection of ESBL genotypes by multiplex PCR amplification:** Multiplex PCR was used to check for the presence of *bla*SHV, *bla*CTX-M, and *bla*TEM genes in the isolates that tested positive for ESBL production in the first screening test13. This approach was somewhat modified from that used by Monstein *et al.* 12. Using a PrestoTM Mini gDNA bacterial kit, freshly cultivated isolates of bacteria were utilized to prepare template deoxyribonucleic acid (DNA). 0.2 units/μl Ampliqon Taq DNA polymerase, 0.4 mM of each dNTP, 0.4 μM of each primer, and 2 μl DNA template (density of 10 ng/μl) were used in all PCR reactions. The Master Mix included 20 mM Tris-HCl pH 8.5, 0.2% Tween® 20, 3 mM MgCl2, and (NH4)2S04. The following settings were made for the polymerase chain reaction amplification: a 10-minute main denaturation step at 95°C; thirty denaturation cycles at 94°C for 30 seconds; annealing at 60°C for 30 seconds; an extension step at 72°C for two minutes; and a final extension step at 72°C for ten minutes. Size separation PCR amplicons were used in conjunction with agarose gel electrophoresis to identify the corresponding genes (Table 1).

**RESULTS**

Twenty successive non-duplicate *E. coli* isolates were recovered in total, and tests were performed on their antimicrobial resistance profile against 23 distinct antimicrobial drugs. The current results revealed that *E. coli* isolates vary widely to different antimicrobials. The resistance rates of isolates of *E. coli* against the selected 23 antimicrobial agents obtained from blood of ICU patients. It was found that a majority of the *E. coli* isolates were resistant to several drugs (multi-drug resistant: MDR) where a total of 17/20 (85%) of *E. coli* isolates indicated MDR phenotypes. Furthermore, the results of the antimicrobial susceptibility test against *E. coli* revealed that *E. coli* showed 45% resistance to Amoxicillin+Clavulanic acid (Table 2), whereas susceptibility to ciprofloxacin decreased to 35%. The highest sensitivity rate of *E. coli* was for aminoglycosides classes were it was 95% for amikacin and 90% forgentamicin. Whereas, the highest resistant rate was for the 1st ,2nd, 3rd and 4th generations of Cephalosporins β-lactam class (80%, 90%, 95%, 90%, 95%, 85% and 100%, respectively) (Table 2). Co-trimoxazole with resistance rates 70%, and 70% respectively. Out of the 20 *E. coli* isolates, a total of 6 isolates (30%) showed positive results in initial screening test of ESBL production by MDDST and phenotypic confirmatory test of ESBL production. In PCR detection of ESBL genotypes, it was found that all of the ESBL screening positive *E. coli* isolates had one or more ESBL genes that were tested in the present study. Overall, 30% (6/20) of *E. coli* isolates were positive for one or more ESBL genes. The multiplex PCR assay results indicated that 100% *bla*TEM genes, 33.3% *bla*CTXM and *bla*SHV genes were not detected in the *E. coli* isolates.

**DISCUSSION**

Antimicrobial resistance in pathogenic bacteria is a global concern that is associated with elevated rates of morbidity and mortality. Furthermore, infections have been reported to be difficult or impossible to treat with traditional antimicrobials due to multidrug resistance patterns. Antibiotics are widely, generously, and usually needlessly utilized because many healthcare facilities fail to identify the underlying bacteria and their patterns of antimicrobial sensitivity in a timely manner in patients with bacteremia and other serious diseases13. High prevalence of MDR *E. coli* isolates was found in the blood clinical samples used in the current study. MDR traits were seen in 85% of the *E. coli* isolates overall. Thirty percent of the *E. coli* MDR isolates were ESBL producers. Unlike the findings of Bora *et al.* 14, which stated that 75% of *E. coli* isolates produced ESBL.

The findings of the test of antimicrobial susceptibility against *E. coli* in the current investigation showed that the susceptibilities of the isolated bacteria to the tested antimicrobials varied. Antimicrobial susceptibilities patterns were identified in all isolates. Similar findings were reported by Tabar *et al*.3 and Liao *et al*. 15. Amino glycosides and carbapenems are frequently the last effective treatments for infections caused by MDR Enterobacteriaceae16. Imipenem and Meropenem, which have been reported to be the most effective antibiotic, including the isolates that create ESBLs, showed 100% sensitivity, according to previous investigations. Given that carbapenemes can be used to treat a variety of infections, this is a significant finding of the current study. This outcome may be explained by the fact that these antibiotics are less common in this area due to their higher cost.

 According to Paterson *et al*.17, ESBL producers are inherently resistant to all cephalosporins, even if they exhibit an in vitro susceptibility. In the current investigation, the percentage of ESBL-producing *E. coli* from all-isolated samples was 6 (30%), while the percentage of non-ESBL-producing *E. coli* was 14 (70%). In fact, people in hospitals all across the world are said to struggle with ESBLs. Additionally, it has been noted that the prevalence rates of ESBLs among clinical isolates vary widely across the globe and that these rates rapidly fluctuate over time18. It is imperative to develop laboratory testing methods to properly determine the presence of such enzymes in clinical isolates, given the rising incidence of *Enterobacteriaceae* that produce ESBLs19. Modified double disc synergy tests were the most sensitive of all the ESBL detection techniques 20. Similar results were found in a study by Khan *et al*. 21, which showed that 6/20 isolates had positive MDDST results and that 6/20 isolates had positive double disk synergy test (DDST) results. Thirty percent of *E. coli* isolates were screened for ESBL production by adhering to the MDDST screening criteria. The presence of one or more ESBL genes in every isolate that passed screening indicated that *E. coli* isolates that produce ESBL are quite common in the area that is being studied. Kaur *et al.* 22 found that 63.4% of *E. coli* isolates from India produced ESBL. The subtypes of ESBL cannot be identified by phenotypic testing, which only validate the production of ESBL. Nüesch-Inderbinen *et al.*23 observed that although molecular approaches have been shown to be sensitive, they are expensive, time-consuming, and require specialist equipment. Only molecular detection techniques are likely to lead to the final identification. According to a research by Navon-Venezia *et al.,*24, the performance of these phenotypic tests must be regularly assessed because the introduction of new enzymes may alter it. Grover *et al.*25 reported that PCR is a dependable technique for ESBL identification in their investigation of phenotypic and genotypic ESBL detection strategies. The multiplex PCR amplification assay was used in this study to identify the *bla*CTX-M, *bla*SHV, and *bla*TEM genes in the *E. coli* clinical isolates that were recovered. This assay has the advantage of allowing for the quick screening of a large number of clinical isolates, and it can also be used to isolate DNA for use in subsequent molecular epidemiological studies if necessary12. Furthermore, a trustworthy epidemiological study into antibiotic resistance requires the identification of beta-lactamase. In the current investigation, E. Coli isolates taken from the bloodstream of ICU patients clinically suspected of having blood sptecimia in Sana'a, Yemen, were surveyed for antimicrobial drug resistance, ESBL phenotypes, and the identification of blaSHV, blaTEM, and blaCTX-M genes.

 Compared to SHV and TEM ESBLs, CTX-M-type ESBLs proved to be the most prevalent kind of ESBL worldwide, with a greater prevalence in most locales26, 27. The study revealed that out of the three ESBL genotypes examined, *bla*TEM 6/6 (100%) and *bla* CTX-M 2/6 (33.3%) were the most commonly occurring in *E. coli* isolates that produced ESBL. The *bla*SHV was the least common ESBL genotype, with a prevalence rate of 0% in ESBL-producing *E. coli* isolates. Similar results were found in studies carried out in Iraq by Manoharan *et al.*28 and Pishtiwan and Khadija26. However, TEM ESBL was the most common genotype in our investigation, whereas *bla*SHV-type ESBL was less common. Since just a small sample size of strains from Sana'a city were gathered and analyzed for this study, it is considered that geographical variances are the cause of the discrepancy.

 Moreover, earlier research conducted in Yemen has revealed that *E. coli* resistance to third-generation cephalosporins is common there29–38. Furthermore, the outbreak reached 50% in Egypt and Syria39, over 70% in Iraq26, and so forth. Moreover, 5–15% of participants in our sample showed susceptibility to all cephalosporins; this incidence is higher than that found in other Arabian countries26,28,39.

 The study revealed that of the three ESBL genotypes examined, *bla*TEM [6/6 (100%)] and CTX-M [2/6 (33.3%)] were the most commonly occurring in *E. coli* isolates that produced ESBL. Naturally, based on the aforementioned findings, a number of investigations by Teawtrakul *et al.*40, Girmenia *et al.*41, Ricciardi *et al*. 42, and Devrim *et al*.43 have demonstrated that different nations have different rates and types of *Escherichia* strains identified. These results demonstrate the need for organized national programs in the area that focus on antimicrobial supervision and infection prevention.

**LIMITATIONS OF THE STUDY**

The following were the study's limitations. Initially, we were unable to precisely identify the kinds of isolates and their pattern of antibiotic sensitivity for Yemen since the data only came from one place (Sana'a city). Confirming the true prevalence of bacterial resistance genes requires molecular study on a large sample size of isolates.

**CONCLUSIONS**

Knowledge of the antimicrobial resistance patterns and resistance genes of bacterial pathogens in a geographical area is important for control and surveillance of antibiotic resistance. The results of the present study revealed that MDR was highly prevalent. In addition, the carbapenems and amino glycosides were found to be the most active antimicrobial agents *in vitro*. Based on the results obtained in the present study, TEM was highly prevalent among other types of ESBLs genes.

**ACKNOWLEDGMENTS**

For their collaboration and support, we thank and appreciate all the medical staff at Kuwait, Al‑Jumhuri, Al-Sabeen, and Al-Thawra hospitals in Sana'a. We also acknowledge Sana’a University's assistance.

**CONFLICT OF INTEREST**

This work does not include any conflicts of interest.

**AUTHOR CONTRIBUTIONS**

Eshtiaq A. Al-Yousafi, the study's first author, conducted the fieldwork as part of his PhD studies at Sana'a University's Faculty of Medicine and Health Sciences' Department of Medical Microbiology. Additional authors contributed to the data analysis, the writing, reviewing, and final approval of the work.

**REFERENCES**

1.Ojdana D, Sacha P, Wieczorek P,Czaban S, Michalska A, Jaworowska J. The Occurrence of blaCTX-M, blaSHV, and blaTEM Genes in Extended-Spectrum β-Lactamase-Positive Strains of *Klebsiella* *pneumoniae*, *Escherichia coli*, and *Proteus mirabilis* in Poland. Intern J Antibi Volume 2014, Article ID 935842, 7 pages https://doi.org/10.1155/2014/935842

2.Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005 ;18(4):657-86. <https://doi.org/10.1128/CMR.18.4.657-686.2005>. PMid:16223952 PMCid:PMC1265908

3.Liao K, Chen Y, Wang M, Guo P, Yang Q, Ni Y, Yu Y, Hu B, Sun Z, Huang W. Molecular characteristics of extended-spectrum β-lactamaseproducing *Escherichia coli* and *Klebsiella pneumoniae* causing intra-abdominal infections from 9 tertiary hospitals in China. Diagn Microbiol Infect Dis. 2017;87(1):45-48 <https://doi.org/10.1016/j.diagmicrobio.2016.10.007>. PMid:27773544

4.Malloy AM, Campos JM. Extended-spectrum beta-lactamases: a brief clinical update. Pediatr Infect Dis J. 2011;30(12):1092-3. <https://doi.org/10.1097/INF.0b013e31823c0e9d>. PMid:22105419

5.Akpaka PE, Legall B, Padman J. Molecular detection and epidemiology of extended-spectrum beta-lactamase genes prevalent in clinical isolates of *Klebsiella pneumoniae* and *E. coli* from Trinidad and Tobago. West Indian Med J. 2010;59(6):591-6

6.Fraser A, Paul M, Almanasreh N, Tacconelli E, Frank U, Cauda R, Borok S, Cohen M, Andreassen S, Nielsen AD, Leibovici L; TREAT Study Group. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med. 2006;119(11):970-6. <https://doi.org/10.1016/j.amjmed.2006.03.034>. PMid:17071166

7.Livermore DM, Paterson DL. Pocket Guide to Extended-spectrum [beta]-lactamases in Resistance. Current Medicine Group, London, UK. 2006

8.Sharma J, Sharma M, Ray P. Detection of TEM & SHV genes in *Escherichia coli* & *Klebsiella pneumoniae* isolates in a tertiary care hospital from India. Indian J Med Res. 2010;132:332-6.

9.Collee JG, Miles RS , WB. Tests for the identification of bacteria In: Collee JG, Fraser AG, Marmion BP and S. A (eds.), Mackie & McCartney practical medical microbiology. Churchill Livingstone, Edinburgh. 1996

10.Wayne P. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing. 2011

11.Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB, Bonomo RA; International Klebsiella Study Group. Extended-spectrum β-lactamases in *Klebsiella pneumoniae* bloodstream isolates from seven countries: Dominance and widespread prevalence of SHV-and CTX-M type β-lactamases. Antimicrob Agents Chemother. 2003;47(11):3554-60.

12.Monstein HJ, Ostholm-Balkhed A, Nilsson MV, Nilsson M, Dornbusch K, Nilsson LE. Multiplex PCR amplification assay for the detection of blaSHV, blaTEM and blaCTX‐M genes in *Enterobacteriaceae*. APMIS. 2007;115(12):1400-8. <https://doi.org/10.1111/j.1600-0463.2007.00722.x> PMid:18184411

13.Akova M. Epidemiology of antimicrobial resistance in bloodstream infections. Virulence, 2016;7:252-266.

14.Bora A, Hazarika NK, Shukla SK, Prasad KN, Sarma JB, Ahmed G. Prevalence of blaTEM, blaSHV and blaCTX-M genes in clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* from Northeast India. Indian J Pathol Microbiol. 2014;57(2):249-54. <https://doi.org/10.4103/0377-4929.134698>. PMid:24943758

15.Tabar MM, Mirkalantari S, Amoli RI. Detection of ctx-M gene in ESBL-producing *E. coli* strains isolated from urinary tract infection in Semnan, Iran. Electron Physician. 2016;8(7):2686-90.

16.Pitout JD. The latest threat in the war on antimicrobial resistance. The Lancet Infectious Diseases, 2010;10:578-579.

17. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, McCormack JG, Yu VL. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39(6):2206-12.

18. Babypadmini S, Appalaraju B. Extended spectrum-lactamases in urinary isolates of *Escherichia coli* and *Klebsiella pneumoniae*-prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol. 2004;22(3):172-4.

19. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14(4):933-51.

20. Modi D, Patel D., Patel S., Jain M., Bhatt S, Vegad M. Comparison of various methods for the detection of extended spectrum beta lactamase in *Klebsiella pneumoniae* isolated from neonatal Intensive Care Unit, Ahmedabad. Natl J Med Res. 2012; 2(3): 348-353.

21. Khan MK, Thukral SS, Gaind R. Evaluation of a modified double-disc synergy test for detection of extended spectrum β-lactamases in AMPC β-lactamase-producing *Proteus mirabilis*. Indian J Med Microbiol. 2008;26(1):58-61. <https://doi.org/10.4103/0255-0857.38860>. PMid:18227600

22. Kaur J, Chopra S, Sheevani, Mahajan G. Modified double disc synergy test to detect ESBL production in urinary isolates of *Escherichia coli* and *Klebsiella pneumoniae*. J Clin Diagn Res. 2013;7(2):229-33

23.Nüesch-Inderbinen MT, Hächler H, Kayser FH. Detection of genes coding for extended-spectrum SHV beta-lactamases in clinical isolates by a molecular genetic method, and comparison with the E test. Eur J Clin Microbiol Infect Dis. 1996;15(5):398-402.

24. Navon-Venezia S, Hammer-Munz O, Schwartz D, Turner D, KuzmenkoB, Carmeli Y. Occurrence and phenotypic characteristics of extended spectrum β-lactamases among members of the family *Enterobacteriaceae* at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests. J Clin Microbiol. 2003;41(1):155-8.

25. Grover SS, Sharma M, Chattopadhya D, Kapoor H, Pasha ST, Singh G.Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in *Klebsiella pneumoniae*: emergence of high resistance against cefepime, the fourth generation cephalosporin. J Infect. 2006 ;53(4):279-88.

26. Pishtiwan A.H., Khadija Kh.M. Prevalence of *bla*TEM, *bla*SHV, and *bla*CTX-M genes among ESBL-producing *Klebsiella pneumoniae* and *Escherichia coli* isolated from thalassemia patients in Erbil, Iraq . Mediterr J Hematol Infect Dis 2019, 11(1): e2019041, http://dx.doi.org/10.4084/MJHID.2019.041

27.Jorgensen JH, McElmeel ML, Fulcher LC, Zimmer BL. Detection of CTX-M-type extended-spectrum beta-lactamase (ESBLs) by testing with MicroScan overnight and ESBL confirmation panels. J Clin Microbiol. 2010;48(1):120-3. <https://doi.org/10.1128/JCM.01507-09>. PMid:19889896 PMCid:PMC2812268

28. Manoharan A, Premalatha K, Chatterjee S, Mathai D; SARI Study Group. Correlation of TEM, SHV and CTX-M extended-spectrum beta lactamases among Enterobacteriaceae with their in vitro antimicrobial susceptibility. Indian J Med Microbiol. 2011;29(2):161-4. <https://doi.org/10.4103/0255-0857.81799> PMid:21654112

29. Alyahawi A, Alkaf A, Alnamer R, Alnosary T. Study of resistance for recently marketed carbapenem drug among hospitalised patients in Sana’a, Yemen. Universal J Pharm Res 2018; 3(5). *https://doi.org/10.22270/ujpr.v3i5.203*

30. Saleh AAM, Al-Shamahy HA, Al-Hrazi RMA, Jaadan BM, AL-Magrami RTF, Al-Sharani AA.Biofilm formation and antibiotic susceptibility of uropathogens in patients with catheter associated urinary tract infections in Ibb city -Yemen. Universal J Pharm Res 2020; 4(6):1-7 *https://doi.org/10.22270/ujpr.v4i6.329*

31. Ishak AA, Alhadi AM, Al-Moyed KAA, Al-Shamahy HA. Childhood urinary tract infection: clinical signs, bacterial causes and antibiotic susceptibility. Universal J Pharm Res 2021; 6(4):58-64. *https://doi.org/10.22270/ujpr.v6i4.643*

32. Al-Shehari, MM,. Al-Khamesy, KSA, Al-Moyed, KA, *et al.* Distribution and antibacterial resistance of wound pathogenic bacteria in patients of Sana’a hospitals, Yemen. Universal J Pharm Res 2023; 8(3):1-8. *https://doi.org/10.22270/ujpr.v8i3.942.*

33. Al-Hammadi, MA, Al-Shamahy, HA, Qaid AA. The prevalence and phenotypic characterization of extended-spectrum β-lactamases-producing Escherichia coli strains isolates recovered from tertiary hospitals in Sana’a city, Yemen. Universal J Pharm Res 2019; 3(6):1-6. *https://doi.org/10.22270/ujpr.v3i6.220*

34. Al-Shami HZ, Al-Haimi MA, Al-dossary OAE, *et al.* Patterns of antimicrobial resistance among major bacterial pathogens isolated from clinical samples in two tertiary’s hospitals, in Sana'a, Yemen. Universal J Pharm Res 2021; 6(5):60-67. *https://doi.org/10.22270/ujpr.v6i5.674*

35. Al-Safani AA, Al-Shamahy H, Al-Moyed K. Prevalence, antimicrobial susceptibility pattern and risk factors of MRSA isolated from clinical specimens among military patients at 48 medical compound in Sana’a city-Yemen. Universal J Pharm Res 2018; 3(3):40-44. *https://doi.org/10.22270/ujpr.v3i3.165*

36. Al-Haifi, AY, Al Makdad, ASM, Salah MK, Al-Shamahy, HA, Al Shehari WAA. Epidemiology, bacterial profile, and antibiotic sensitivity of lower respiratory tract infections in Sana’a and Dhamar city, Yemen. Universal J Pharm Res 2020; 5(2):1-8. *https://doi.org/10.22270/ujpr.v5i2.386*

37. Al-Haifi AY, Al Makdad ASM, Salah MK, Al-Shamahy HA. Urinary tract infections in post operative patients: prevalence rate, bacterial profile, antibiotic sensitivity and specific risk factors. Universal J Pharm Res 2020; 5(3):1-6. *https://doi:10.22270/ujpr.v5i3.411*

38.Al-Huraibi BS, Al-Shehari M, Al-Moyed KA, Al-Shami HZ, Al-Hymia FM, Al-Shamahy HA. Comparison of antibiotic sensitivity of MRSA with MSSA among *Staphylococcus aureus* isolates from patients in the 48 military hospital in Sana'a city, Yemen. Universal J Pharm Res 2023; 8(4):47-52.*https://doi.org/10.22270/ujpr.v8i4.974*

39. Moghnieh RA, Kanafani ZA, Tabaja HZ, Sharara SL, Awad LS, Kanj SS. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. Lancet Infect Dis. 2018;18(12):e379-e394 https://doi.org/10.1016/S1473-3099(18)30414-6

40.Teawtrakul N, Jetsrisuparb A, Sirijerachai C, Chansung K, Wanitpongpun C. Severe bacterial infections in patients with nontransfusion- dependent thalassemia: prevalence and clinical risk factors. Int J Infect Dis. 2015 ;39:53-6. https://doi.org/10.1016/j.ijid.2015.09.001.PMid:26358855

41.Ricciardi W, Giubbini G, Laurenti P. Surveillance and Control of Antibiotic Resistance in the Mediterranean Region. Mediterr J Hematol Infect Dis. 2016;8(1):e2016036. <https://doi.org/10.4084/mjhid.2016.036> PMid:27413528 PMCid:PMC4928537

42. Devrim F, Serdaroğlu E, Çağlar İ, Oruç Y, Demiray N, Bayram N, Ağın H, Çalkavur S, Sorguç Y, Dinçel N, Ayhan Y, Yılmaz E, Devrim I. The Emerging Resistance in Nosocomial Urinary Tract Infections: From the Pediatrics Perspective. Mediterr J Hematol Infect Dis. 2018 1;10(1):e2018055. https://doi.org/10.4084/mjhid.2018.055.PMid:30210748 PMCid:PMC6131100

43. Girmenia C, Serrao A, Canichella M. Epidemiology of Carbapenem Resistant Klebsiella pneumoniae Infections in Mediterranean Countries. Mediterr J Hematol Infect Dis. 2016; 8(1):e2016032. <https://doi.org/10.4084/mjhid.2016.032>. PMid:27441063 PMCid:PMC4943068

44. Lee J, Pai H, Kim YK, Kim NH, Eun BW, Kang HJ, Park KH, Choi EH, Shin HY, Kim EC, Lee HJ, Ahn HS. Control of extended-spectrum beta-lactamase producing *Escherichia coli and Klebsiella pneumoniae*  in a children’s hospital by changing antimicrobial agent usage policy. J Antimicrob Chemother 60:629– 37, 2007

45. Pai H, Hong JY, Byeon JH, Kim YK, Lee HJ. High prevalence of extended-spectrum beta-lactamasesproducing strains among blood isolates of *Enterobacter* spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns. Antimicrob Agents Chemother 48:3159–61, 2004

**Results**

Table 1**:** The frequency of isolated bacteria from ICUs patient’s blood cultures in the selected hospitals in Sana’a city.

|  |  |  |
| --- | --- | --- |
| **Micro-organisms** | **No.** | **%** |
| **Gram positive bacteria** | **42** | **43.7** |
| Coagulase negative *Staphylococci* | 25 | 26 |
| *Staphylococcus aureus* | 9 | 9.4 |
| *Streptococcus pneumoniae* | 5 | 5.2 |
| *Enterococci* | 2 | 2.1 |
| *Streptococcus pyogenes* | 1 | 1.0 |
| **Gram negative bacteria** | **50** | 52.1 |
| *Escherichia coli* | 20 | 20.8 |
| *Klebsiella species* | 11 | 11.5 |
| *Burkholderia cepacia* | 6 | 6.3 |
| *Haemophilus influenzae*  | 5 | 5.2 |
| *Acinetobacter baumannii* | 4 | 4.2 |
| *Pseudomonas aeruginosa* | 3 | 3.1 |
| *Chryseobacterium indologenes* | 1 | 1.0 |

Table 2**:** The antibiotics susceptibility for the total 20 *E. coli* isolated from sepsis patients of ICU.

|  |  |  |  |
| --- | --- | --- | --- |
| **Antibiotics name** | **Classes** | **Sensitive** | **Resistant** |
| **No.** | **%** | **No.** | **%** |
| 1. Ampicillin
 | Penicillin/amino-penicillin | 5 | 25 | 15 | 75 |
| 1. Piperacillin- Tazobactam
 | Penicillin and β- lactamase inhibitor | 12 | 60 | 8 | 40 |
| 1. Amoxicillin-Clavulanate
 | 11 | 55 | 9 | 45 |
| 1. Cefazoline
 | 1st generation | 0 | 0 | 20 | 100 |
| 1. Cefadroxil
 | 1 | 5 | 19 | 95 |
| 1. Cephradin
 | 4 | 20 | 15 | 80 |
| 1. Cefoxitin
 | 2nd generation | 2 | 10 | 18 | 90 |
| 1. Cefuroxime
 | 1 | 5 | 19 | 95 |
| 1. Ceftazidime ESBL
 | 3rd generation | 2 | 10 | 18 | 90 |
| 1. Cefotaxime ESBL
 | 1 | 5 | 19 | 95 |
| 1. Ceftriaxone
 | 3 | 15 | 17 | 85 |
| 1. Cefoperazone
 | 2 | 10 | 18 | 90 |
| 1. Cefepime
 | 4th generation | 2 | 10 | 18 | 90 |
| 1. Imipenem
 | Carbapenems | 14 | 70 | 6 | 30 |
| 1. Meropenem
 | 16 | 80 | 4 | 20 |
| 1. Aztreonam
 | Monobactams  | 8 | 40 | 12 | 60 |
| 1. Amikacin
 | Aminoglycosides | 19  | 95 | 1 | 5 |
| 1. Gentamicin
 | 18 | 90 | 2 | 10 |
| 1. Co-Trimoxazole
 | Folate pathway inhibitors | 5 | 25 | 15 | 75 |
| 1. Ciprofloxacin
 | Fluoroquinolones | 7 | 35 | 13 | 65 |
| 1. Levofloxacin
 | 10 | 50 | 10 | 50 |
| 1. Norfloxacin
 | 6 | 30 | 14 | 70 |
| 1. Moxifloxacin
 | 8 | 40 | 12 | 60 |

Table 3: The ESBL producing *E. coli* (**No.=20**) isolated from the blood sample of ICUs patients.

|  |  |  |
| --- | --- | --- |
| **ESBL producing** | **No.** | **%** |
| Negative | 14  | 70 |
| Positive | 6  | 30 |

Table 4**:** The prevalence rate of ESBL genes of ESBL-producing *E. coli* isolated from the blood sample of ICUs patients.

|  |  |  |  |
| --- | --- | --- | --- |
| **ESBL genes** | ***bla*TEM** | ***bla*CTX-M** | ***bla*SHV** |
| **No.**  | **%** | **No.** | **%** | **No.** | **%** |
| Negative | 0 | 0 | 4 | 66.7 | 6 | 100 |
| Positive | 6 | 100 | 2 | 33.3 | 0 | 0 |

Table 5 **:** List of primers used for Multiplex PCR amplification.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Target gene | Primer | Sequence (5’-3’) | Amplicon size**bp** | References |
| *bla*TEM | Forward | ATGAGTATTCAACATTTCCG | 847 | lee *et al.*, 200744 |
| Reverse | GTCACAGTTACCAATGCTTA |
| *bla*SHV | Forward | GATGAACGCTTTCCCATGATG | 214 |  Pai *et al*., 2004 45 |
| Reverse | CGCTGTTATCGCTCATGGTAA |
| *bla*CTX-M | Forward | GTTACAATGTGAGAAGAG | 1018 |  lee *et al.*, 2007 44 |
| Reverse | CCGTTTCCGCTATTACAAAC |